Anti-aggregative effects of pyridoxal-5′-phosphate on platelet morphological changes

Wen Jen Yu, Ru Chun Dai, Sue-Joan Chang

Research output: Contribution to journalArticlepeer-review

Abstract

Pyridoxal-5′-phosphate (PLP), the active form of vitamin B6, was previously studied in our laboratory as a potential anti-aggregative agent which has beneficial effects in preventing cardiovascular diseases. However, the relationship between the anti-aggregative effects and morphological changes of PLP is unclear. In this study, platelet-rich plasma (PRP) was respectively activated by thrombin, ADP, and collagen and co-incubated with the tetrapeptide, Arg-Gly-Asp-Ser (RGDS), or PLP. Morphological changes in platelets were evaluated by scanning electronic microscopy (SEM). The results indicated that optimal aggregative concentrations of thrombin, ADP, and collagen were 0.5 units/mL, 25 μM, and 0.1 mg/mL, respectively. Meanwhile, the optimal anti-aggregative concentrations of PLP and RGDS to those platelet agonists were 1.5 and 0.23 mM, respectively. The SEM data showed that morphological changes in platelet by RGDS or PLP treatment were similar, including lower activation, being sustained in the pseudopod stages, and having smaller fibrin spindles during thrombin induction. The smaller fibrin spindle formation caused by PLP or RGDS might be helpful in preventing blood coagulation. In this study, we provide morphological evidence that the anti-aggregative effect of PLP is partially similar to that of RGDS in inhibiting fibrinogen binding to GP23 receptors.

Original languageEnglish
Pages (from-to)98-108
Number of pages11
JournalNutritional Sciences Journal
Volume35
Issue number3
Publication statusPublished - 2010 Sep 1

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Fingerprint Dive into the research topics of 'Anti-aggregative effects of pyridoxal-5′-phosphate on platelet morphological changes'. Together they form a unique fingerprint.

Cite this